Given xenin has confirmed GIP-potentiatingactions, the combination of therapies that increase xenin bioactivity alongsideestablished DPP-4 inhibitor drugs clearly warrants further consideration as a noveltherapeutic option in the management of type 2 diabetes mellitus in humans. Here, COPA is linked to diabetes mellitus.